OPEN ACCESS Freely available online

ISSN: 0975-0851
Journal of Bioequivalence & Bioavailability

Perspective

Therapeutic Equivalence in Pharmacogenomics and Generic Drug Development

Shawn Zhang*

Department of Pharmacology, Shantou University, Shantou, China

DESCRIPTION

Therapeutic Equivalence (TE) is a critical concept in pharmaceutical sciences, particularly in the development and approval of generic drugs. It assures that a generic drug product performs in the same manner as its Reference-Listed Drug (RLD) counterpart in terms of efficacy and safety. This equivalence is evaluated through Bioequivalence (BE) studies, which compare the pharmacokinetic profiles of the two formulations. By demonstrating bioequivalence, a generic drug can be deemed therapeutically equivalent, paving the way for its approval and widespread use.

Understanding therapeutic equivalence

Therapeutic equivalence encompasses two essential criteria:

Pharmaceutical equivalence: The generic drug must have the same active ingredient, dosage form, strength, and route of administration as the RLD.

Bioequivalence: The generic and reference products must exhibit comparable bioavailability, typically assessed through parameters like the Area Under the Curve (AUC) and the maximum concentration (Cmax) of the drug in the bloodstream.

Together, these criteria ensure that the generic drug provides the same therapeutic benefits as the RLD without compromising safety or efficacy. Regulatory agencies such as the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) rely on these principles to approve generic medications.

Role of bioequivalence in therapeutic equivalence

Bioequivalence studies form the backbone of therapeutic equivalence assessment. These studies are usually conducted in healthy volunteers under tightly controlled conditions. The primary goal is to compare the pharmacokinetics of the generic and reference drugs, ensuring that their rate and extent of absorption are within an acceptable range.

Key elements of bioequivalence studies

Study Design is used, where each participant receives both the generic and reference products in separate periods. AUC and Cmax are the most critical parameters for assessing bioequivalence. AUC reflects the total drug exposure, while Cmax represents the peak drug concentration. Bioequivalence is established using statistical methods that ensure the pharmacokinetic parameters of the generic drug fall within the predefined equivalence range.

Challenges in establishing therapeutic equivalence

While the concept of therapeutic equivalence is straightforward, its implementation can be challenging due to several factors:

Complex drug formulations: Biologics and biosimilars: Unlike small-molecule drugs, biologics are large, complex molecules produced through biotechnological processes. Their therapeutic equivalence requires demonstrating biosimilarity, a more rigorous standard than bioequivalence.

Modified-release formulations: Extended-release and delayed-release formulations pose unique challenges due to their complex release mechanisms, necessitating additional studies to ensure therapeutic equivalence.

Highly variable drugs: Some drugs exhibit high inter-individual variability in their pharmacokinetics, making it difficult to establish bioequivalence. Regulatory agencies often provide guidance for such drugs, allowing for wider bioequivalence criteria or alternative study designs.

Special populations: Bioequivalence studies are typically conducted in healthy volunteers, which may not reflect the drug's behavior in special populations such as pediatric, elderly, or renally impaired patients.

***In Vitro-In Vivo* Correlation (IVIVC):** Establishing a robust IVIVC is necessary for predicting bioequivalence based on *in vitro* dissolution studies. However, achieving this correlation is challenging, especially for complex formulations.

Correspondence to: Shawn Zhang, Department of Pharmacology, Shantou University, Shantou, China, E-mail: zhangs@js-p2.cn

Received: 26-Nov-2024, Manuscript No. JBB-24-28061; **Editor assigned:** 28-Nov-2024, PreQC No. JBB-24-28061 (PQ); **Reviewed:** 11-Dec-2024, QC No. JBB-24-28061; **Revised:** 18-Dec-2024, Manuscript No. JBB-24-28061 (R); **Published:** 25-Dec-2024, DOI: 10.35248/0975-0851.24.16.610.

Citation: Zhang S (2024). Therapeutic Equivalence in Pharmacogenomics and Generic Drug Development. J Bioequiv Availab. 16:610.

Copyright: © 2024 Zhang S. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Therapeutic equivalence beyond generics

While therapeutic equivalence is most commonly associated with generic drugs, its principles are also relevant in other contexts:

Biosimilars: Biosimilars are biologic products that are highly similar to an approved reference biologic. Establishing therapeutic equivalence for biosimilars involves demonstrating no clinically meaningful differences in efficacy, safety, and immunogenicity.

Drug substitution: Therapeutic equivalence is necessary for interchangeable products, allowing pharmacists to substitute generic or biosimilar products for their reference counterparts without requiring prescriber approval.

Global health: In resource-limited settings, demonstrating therapeutic equivalence is vital for ensuring the quality of locally manufactured drugs, particularly for diseases like HIV, malaria, and tuberculosis.

CONCLUSION

Therapeutic equivalence, underpinned by bioequivalence, is a cornerstone of modern pharmaceutical development. It ensures that generic and biosimilar drugs meet the same standards of efficacy and safety as their reference products, fostering competition and improving access to affordable medications. Despite the challenges, ongoing advancements in science, technology, and regulatory frameworks promise to refine the assessment of therapeutic equivalence, benefiting patients worldwide.